Staphylococcus aureus bacteremia
Conditions
Brief summary
The primary outcome is success of therapy, defined at 180 days after randomization by presence of the following: 1. Patient alive. 2. No evidence of microbiologically confirmed disease relapse, defined as symptoms and/or signs of infection, after initial clinical improvement, with S. aureus isolated from blood or another normally sterile site (e.g. joint fluid, tissue) by conventional culture.
Interventions
DRUGCEFAZOLINE LDP-LABORATORIOS TORLAN 2 g
DRUGpoudre pour solution injectable/pour
perfusion
DRUGFlucloxacillin 250mg Powder for Solution for Injection or Infusion
DRUGhard
Sponsors
Stichting Amsterdam UMC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is success of therapy, defined at 180 days after randomization by presence of the following: 1. Patient alive. 2. No evidence of microbiologically confirmed disease relapse, defined as symptoms and/or signs of infection, after initial clinical improvement, with S. aureus isolated from blood or another normally sterile site (e.g. joint fluid, tissue) by conventional culture. | — |
Countries
Netherlands
Outcome results
None listed